Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
NCT03943615 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-07-18
Summary
The intent of this open-label, multicenter expanded access program (EAP) is to provide early access to voxelotor prior to market authorization
Conditions
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Voxelotor Brain Oxygenation and Neurocognitive Study
NCT05228821 ·Status: WITHDRAWN ·Phase: PHASE4
-
Voxelotor CYP and Transporter Cocktail Interaction Study
NCT05981365 ·Status: COMPLETED ·Phase: PHASE1
-
Voxelotor Sickle Cell Exercise Study
NCT04581356 ·Status: COMPLETED ·Phase: PHASE4
-
Retrospective Real World Oxbryta® Data Collection and Analysis Study
NCT04930328 ·Status: COMPLETED
-
Voxelotor Neurocognitive Function Study
NCT05228834 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
NCT05431088 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
NCT06023199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor
NCT05199766 ·Status: UNKNOWN ·Phase: PHASE2
-
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
NCT05618301 ·Status: COMPLETED ·Phase: PHASE1
-
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
NCT02411708 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease
NCT03664830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants
NCT06503458 ·Status: TERMINATED
-
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
NCT05951205 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 ·Status: RECRUITING ·Phase: PHASE3
-
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
NCT00004408 ·Status: COMPLETED ·Phase: PHASE3
-
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
NCT06399107 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
NCT06818266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients
NCT01736657 ·Status: COMPLETED ·Phase: NA
-
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
NCT05632354 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
NCT01000155 ·Status: TERMINATED ·Phase: PHASE2
-
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
NCT05861453 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase Ib Study of NVX-508 in Sickle Cell Disease
NCT03013426 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
NCT02433158 ·Status: TERMINATED ·Phase: PHASE3
-
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
NCT06442761 ·Status: RECRUITING ·Phase: PHASE1
-
Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients
NCT02212535 ·Status: COMPLETED ·Phase: PHASE1/PHASE2